ADVANCE NEXT global phase 3 confirmatory study is open for certain people living with ITP to join. The study, or clinical trial, is looking at a drug called efgartigimod IV for treating primary immune thrombocytopenia (ITP). The study lasts about 2.5 years and includes a screening period, a treatment period, and a follow-up period. During the first 24 weeks, participants will get either the new drug or a placebo. After that, everyone can get the new drug. The study is looking for 69 adults with primary ITP. You may join if you were diagnosed at least a year ago and have tried other treatments that may no longer be working well for you. There is no cost to join, and you may get travel expenses covered. For more details, please contact your hematologist, visit clinicaltrials.gov and search for NCT06544499 or email argenx Patient Advocacy Lead at sgerson@argenx.com.

USA and International

https://clinicaltrials.gov/study/NCT06544499?term=NCT06544499&rank=1

Actively Recruiting